Open AccessTegaserod for the Treatment of Irritable Bowel Syndrome
Author(s) -
Valentioemi Madia,
Antonella Messore,
Francesco Saccoliti,
Valeria Tudino,
Alessandro De Leo,
Daniela De Vita,
Martina Bortolami,
Luigi Scipione,
Ivano Pindinello,
Roberta Costi,
Roberto Di Santo
Publication year - 2020
Publication title -
anti-inflammatory and anti-allergy agents in medicinal chemistry
Language(s) - English
Resource type - Journals
eISSN - 1875-614X
pISSN - 1871-5230
DOI - 10.2174/1871523018666190911121306
Subject(s) - tegaserod , medicine , irritable bowel syndrome , constipation , adverse effect , partial agonist , tolerability , gastroenterology , agonist , receptor
Tegaserod (Zelnorm®) is a 5-hydroxytryptamine (serotonin) type 4 receptor agonist for the treatment of hypomotility disorders of the lower gastrointestinal tract associated with the irritable bowel syndrome with constipation (IBS-C).